Back in 2016, hundreds of jobs were expected for a drug manufacturing plant in the town of Dunkirk. The plant was built but ...

ImmunityBio to receive $75 million in non-dilutive funding under existing Revenue Interest Purchase Agreement (RIPA) with Oberland Capital, bringing total committed capital to $375 million ...

Detailed price information for Immunitybio Inc (IBRX-Q) from The Globe and Mail including charting and trades.

SAN FRANCISCO, March 30, 2026 /PRNewswire/ -- ImmunityBio, Inc. (NASDAQ: IBRX) faces a securities class action lawsuit which seeks to represent investors who purchased or otherwise acquired ...

ImmunityBio closed the first quarter of 2026 with its strongest commercial performance to date, yet its stock price tells a different story. The disconnect highlights a massive bet by traders against ...

CULVER CITY, Calif.--(BUSINESS WIRE)-- ImmunityBio (IBRX), a commercial-stage immunotherapy company, today announced the successful completion of manufacturing engineering programs, NK2022 and NK2023, ...

ImmunityBio completed its NK2022 (Cancer and Healthy Volunteers) and NK2023 (Healthy Volunteers) programs, which evaluated the safety and reproducibility of its autologous memory cytokine-enhanced ...

ImmunityBio IBRX announced its response to a warning letter issued by the FDA last month over “false” or “misleading” promotional statements related to its cancer drug, Anktiva. ImmunityBio stated ...

ImmunityBio has taken proactive steps to address the OPDP’s concerns, including the removal of the identified podcast from its corporate website and requesting its removal from third-party platforms.

BOSTON, March 27, 2026 (GLOBE NEWSWIRE) -- Block & Leviton announces that a securities fraud lawsuit has been filed against ImmunityBio, Inc. (Nasdaq: IBRX) and certain of its executives. Investors ...